GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Cyclically Adjusted Price-to-FCF

TherapeuticsMD (TherapeuticsMD) Cyclically Adjusted Price-to-FCF : (As of Apr. 30, 2024)


View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


TherapeuticsMD Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for TherapeuticsMD's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Cyclically Adjusted Price-to-FCF Chart

TherapeuticsMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TherapeuticsMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TherapeuticsMD's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Cyclically Adjusted Price-to-FCF falls into.



TherapeuticsMD Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

TherapeuticsMD's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, TherapeuticsMD's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.449/129.4194*129.4194
=-0.449

Current CPI (Dec. 2023) = 129.4194.

TherapeuticsMD Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -3.044 99.695 -3.952
201406 -3.503 100.560 -4.508
201409 -3.757 100.428 -4.842
201412 -5.022 99.070 -6.560
201503 -5.869 99.621 -7.625
201506 -7.206 100.684 -9.263
201509 -5.214 100.392 -6.722
201512 -4.794 99.792 -6.217
201603 -5.020 100.470 -6.466
201606 -4.027 101.688 -5.125
201609 -4.832 101.861 -6.139
201612 -4.072 101.863 -5.174
201703 -5.223 102.862 -6.571
201706 -4.525 103.349 -5.666
201709 -4.029 104.136 -5.007
201712 -4.984 104.011 -6.202
201803 -4.576 105.290 -5.625
201806 -5.830 106.317 -7.097
201809 -11.925 106.507 -14.490
201812 -6.002 105.998 -7.328
201903 -8.056 107.251 -9.721
201906 -10.718 108.070 -12.835
201909 -5.705 108.329 -6.816
201912 -13.660 108.420 -16.306
202003 -7.286 108.902 -8.659
202006 -10.363 108.767 -12.331
202009 -6.294 109.815 -7.418
202012 -5.380 109.897 -6.336
202103 -5.589 111.754 -6.472
202106 -3.378 114.631 -3.814
202109 -4.548 115.734 -5.086
202112 -4.801 117.630 -5.282
202203 -2.099 121.301 -2.239
202206 -2.377 125.017 -2.461
202209 1.914 125.227 1.978
202212 2.784 125.222 2.877
202303 -0.892 127.348 -0.907
202306 -0.332 128.729 -0.334
202309 -0.563 129.860 -0.561
202312 -0.449 129.419 -0.449

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TherapeuticsMD  (NAS:TXMD) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


TherapeuticsMD Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


TherapeuticsMD (TherapeuticsMD) Business Description

Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.
Executives
Marlan D Walker officer: General Counsel 951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Joseph Ziegler officer: Principal Financial Officer 1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan officer: CAO and VP of Finance 6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman officer: Chief Business Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts director C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Paul Bisaro director
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jules A. Musing director 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Collins Cooper C. director 33219 FOREST WEST DRIVE, MAGNOLIA TX 77354

TherapeuticsMD (TherapeuticsMD) Headlines

From GuruFocus

TherapeuticsMD Announces Expiration of Tender Offer

By Business Wire Business Wire 07-13-2022

TherapeuticsMD Announces Additional $7 Million Private Placement

By Business Wire Business Wire 10-31-2022